In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

P-wave morphology is unaffected by training-induced biatrial dilatation: a prospective, longitudinal study in healthy athletes

Session Poster session 5

Speaker Assistant Professor Flavio D'Ascenzi

Event : EuroEcho 2015

  • Topic : preventive cardiology
  • Sub-topic : Athlete´s Heart
  • Session type : Poster Session

Authors : F D'ascenzi (Siena,IT), M Solari (Siena,IT), M Cameli (Siena,IT), M Focardi (Siena,IT), D Corrado (Padua,IT), M Bonifazi (Siena,IT), M Henein (Umea,SE), S Mondillo (Siena,IT)

F D'ascenzi1 , M Solari1 , M Cameli1 , M Focardi1 , D Corrado2 , M Bonifazi3 , M Henein4 , S Mondillo1 , 1University of Siena, Department of Medical Biotechnologies, Division of Cardiology - Siena - Italy , 2University of Padova, Department of Cardiac, Thoracic, and Vascular Sciences - Padua - Italy , 3University of Siena, Department of Medicine, Surgery, and NeuroScience - Siena - Italy , 4Umea University Hospital, Department of Cardiology - Umea - Sweden ,

Eur Heart J Cardiovasc Imaging Abstracts Supplement ( 2015 ) 16 ( Supplement 2 ), ii199

Purpose: Biatrial enlargement is common in athletes and a further increase in biatrial size can occur in response to training during the season. Although P-wave mophology seems to be unaffected by atrial size, data based on in-seasonal repeated measures are not available in top-athletes. Thus, the aim of this study was to investigate whether training-induced biatrial enlargement is able to change the ECG pattern in athletes.

Methods: Thirty-three professional, top-level athletes were evaluated at the beginning of the competitive season and after 6 months of training. Twenty-two sedentary subjects were used as controls. ECG and both standard and 2D speckle tracking echocardiography were used.

Results: Athletes had greater left atrial (LA) and right atrial (RA) size as compared with controls (p<.0001). A further increase in left and right atrial size was observed after training (p=.002 and p=.005, respectively). Neither athletes nor controls fulfilled the criteria for RA enlargement. No significant differences exist between athletes and controls for criteria for LA enlargement, although 6% of athletes fullfilled the ECG criteria for LA enlargement. After training, despite an increase in LA size, the percentage of athletes fulfilling these criteria did not vary. Of note, biatrial stiffness was normal both in athletes and in controls.

Conclusions: Despite a greater biatrial size and a further training-induced increase in biatrial dimensions, in top-level athletes ECG criteria for biatrial enlargement do not significantly vary during the season, suggesting that P-wave morphology is unaffected by atrial size. The finding of a normal biatrial stiffness suggests that, in absence of intra-atrial delay and in presence of a physiological remodelling, no pathological findings can be detected at 12-lead ECG.

VariableControlsAthletesathletes vs. controlspre-training vs. post-training

LA volume index, mL/m2

20.7 ± 4.7

27.1 ± 6.6

31.1 ± 8.2



RA volume index, mL/m2

17.3 ± 3.8

23.4 ± 6.3

26.4 ± 6.4



LA enlargement criteria






RA enlargement criteria






Biatrial volumes and ECG criteria for biatrial enlargement in athletes and in controls.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are